Compare Eli Lilly And Co (LLY) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Symbotic Inc — how do they compare? Eli Lilly And Co trades at $1,177.75 (market cap $1.04T), while Symbotic Inc trades at $42.55 (market cap $5.46B). The key difference: Eli Lilly And Co is far larger — about 190.5× Symbotic Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Symbotic Inc for 23 Days on average.
| LLY | SYM | |
|---|---|---|
Market Cap | $1.04T | $5.46B |
Volume | 3,064,878 | 1,965,805 |
Sector | Health | Industrials |
52-Week High | $1.28K | $87.30 |
52-Week Low | $799.57 | $38.22 |
Typical Hold Time | 93 Days | 23 Days |
Enterprise Value | $1.09T | $3.72B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
SYM trades at $42.56, down 1.73% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $16.94 million in 2025, though revenue grew to $2.25 billion. Analysts maintain a consensus Buy rating with a $60.33 price target, citing a robust $22.5 billion backlog and positioning in warehouse automation.
The outlook hinges on execution of its large backlog and diversification beyond key customer Walmart. Near-term risks include recent earnings misses and high valuation multiples relative to current profitability. The stock offers growth potential if margin expansion and recurring revenue targets are met, but faces volatility from execution risks and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
